Form 4 for HRMY Harmony Biosciences Holdings, Inc.
Accepted 2024-03-11 00:00:00 ET · period of report 2024-03-08 · accession 0001415889-24-007527 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-03-11 | 2024-03-08 | HRMY | Dierks Jeffrey | Chief COMMERCIAL Off | S - Sale+OE | $32.00 | -194 | 0 | -100% | -$6,208 |
| D | 2024-03-11 | 2024-03-08 | HRMY | Dierks Jeffrey | Chief COMMERCIAL Off | M - OptEx | $8.22 | +194 | 194 | New | +$1,595 |
| DM | 2024-03-11 | 2024-03-08 | HRMY | Dierks Jeffrey | Chief COMMERCIAL Off | M - OptEx | $0.00 | -194 | 14.5K | -1% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-03-08 | S | D | 194 | $32.00 | 0 | D | — | — | (F2) These shares were sold in a single transaction at a selling price of $32.00. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 2 | Common | Common Stock | 2024-03-08 | M | A | 194 | $8.22 | 194 | D | — | — | |
| 3 | Derivative | Stock Option | 2024-03-08 | M | D | 100 | $0.00 | 2,335 | D | $8.22 · — to 2029-10-01 | 100 Common Stock | (F3) The stock option vests in five equal annual installments beginning on October 1, 2019. |
| 4 | Derivative | Stock Option | 2024-03-08 | M | D | 94 | $0.00 | 14,513 | D | $8.22 · — to 2030-03-04 | 94 Common Stock | (F4) The stock option vests in five equal annual installments beginning on March 1, 2021. |